Detalhe da pesquisa
1.
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.
Cell
; 181(7): 1612-1625.e13, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32497499
2.
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Future Oncol
; 20(7): 351-360, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994649
3.
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Cancer
; 128(6): 1194-1205, 2022 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882781
4.
A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer.
BMC Cancer
; 20(1): 820, 2020 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32859160
5.
Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients.
J Natl Compr Canc Netw
; 18(11): 1446-1452, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152701
6.
Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer.
J Urol
; 202(4): 732-741, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31216253
7.
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
Oncologist
; 23(6): 656-e64, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29487219
8.
When to use somatic tumor testing in prostate cancer.
Clin Adv Hematol Oncol
; 20(8): 487-489, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125954
9.
Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
Int J Cancer
; 134(10): 2284-93, 2014 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24166007
10.
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.
Cancer Immunol Res
; 12(4): 453-461, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38276989
11.
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
J Clin Oncol
; 42(12): 1403-1414, 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215355
12.
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Urol Oncol
; 41(3): 145.e7-145.e15, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36435709
13.
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
J Clin Oncol
; 41(1): 22-31, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041086
14.
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
J Clin Oncol
; 41(25): 4107-4117, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369081
15.
Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study.
J Am Geriatr Soc
; 70(1): 136-149, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34611887
16.
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Eur Urol Oncol
; 5(6): 714-718, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35216942
17.
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
Clin Cancer Res
; 27(18): 5123-5130, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108177
18.
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
J Immunother Cancer
; 9(5)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33986125
19.
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
J Immunother Cancer
; 9(5)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33980590
20.
The double-edged sword of ADT: emerging evidence of cardiovascular, pulmonary, and renal risks.
Oncology (Williston Park)
; 29(1): 67-8, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25592211